UK markets close in 4 hours 7 minutes
  • FTSE 100

    7,557.31
    +48.16 (+0.64%)
     
  • FTSE 250

    20,407.39
    +24.63 (+0.12%)
     
  • AIM

    932.59
    -1.52 (-0.16%)
     
  • GBP/EUR

    1.1873
    +0.0014 (+0.11%)
     
  • GBP/USD

    1.2027
    -0.0032 (-0.26%)
     
  • BTC-GBP

    20,041.25
    -219.05 (-1.08%)
     
  • CMC Crypto 200

    574.23
    -16.53 (-2.80%)
     
  • S&P 500

    4,297.14
    +16.99 (+0.40%)
     
  • DOW

    33,912.44
    +151.39 (+0.45%)
     
  • CRUDE OIL

    89.48
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    1,790.70
    -7.40 (-0.41%)
     
  • NIKKEI 225

    28,868.91
    -2.87 (-0.01%)
     
  • HANG SENG

    19,830.52
    -210.34 (-1.05%)
     
  • DAX

    13,908.39
    +91.78 (+0.66%)
     
  • CAC 40

    6,597.06
    +27.11 (+0.41%)
     

Waldenstrom Macroglobulinemia Epidemiology Forecasts, 2030 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

·4-min read

DUBLIN, November 30, 2021--(BUSINESS WIRE)--The "Waldenstrom Macroglobulinemia - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

The incident cases of Waldenstrom Macroglobulinemia associated in 7MM countries were 3,159 in 2020.

This 'Waldenstrom Macroglobulinemia (WM) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of Waldenstrom Macroglobulinemia, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Waldenstrom Macroglobulinemia - Disease Understanding

Waldenstrom Macroglobulinemia, also referred to as a lymphoplasmacytic lymphoma (LPL) with an associated monoclonal IgM paraprotein, is a rare indolent (slow-growing) B-cell lymphoma that occurs in < 2% of patients with Non-Hodgkin's Lymphoma (NHL). WM usually affects older adults and generally affects the bone marrow but can also occur in the lymph nodes and other tissues and organs of the lymphatic system.

Waldenstrom Macroglobulinemia Epidemiology

The Waldenstrom Macroglobulinemia epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total incident cases of Waldenstrom Macroglobulinemia patients are increasing in 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted WM symptoms epidemiology segmented as the Incidence of Waldenstrom Macroglobulinemia, Gender-specific cases of Waldenstrom Macroglobulinemia, Age-specific Cases of Waldenstrom Macroglobulinemia, and Genetic Mutations in Waldenstrom Macroglobulinemia.

The report includes the incident scenario of Waldenstrom Macroglobulinemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Waldenstrom Macroglobulinemia Epidemiology

The epidemiology segment also provides the Waldenstrom Macroglobulinemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • As per the estimates, the United States has the largest incident population of Waldenstrom Macroglobulinemia.

  • Among the EU5 countries, France had the highest incident cases of Waldenstrom Macroglobulinemia, followed by the UK. On the other hand, Spain had the lowest incident cases with 154 cases in 2020.

Key Questions Answered

  • What will be the growth opportunities in the 7MM for the patient population about Waldenstrom Macroglobulinemia?

  • What are the key findings of the Waldenstrom Macroglobulinemia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?

  • What would be the total number of Waldenstrom Macroglobulinemia patients across the 7MM during the forecast period (2018-2030)?

  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2018-2030)?

  • What are the disease risk, burden, and unmet needs of Waldenstrom Macroglobulinemia?

  • What are the currently available treatments for Waldenstrom Macroglobulinemia?

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Waldenstrom Macroglobulinemia (WM) Market Overview at a Glance

3.1 Market Share (%) Distribution of WM in 2018

3.2 Market Share (%) Distribution of WM in 2030

4 Executive Summary of Waldenstrom Macroglobulinemia (WM)

5 Disease Background and Overview

5.1 Introduction

5.2 Classification of Waldenstrom Macroglobulinemia

5.3 Etiology

5.4 Clinical Manifestations

5.5 Risk Factors

5.6 Pathophysiology

5.7 Prognosis

5.8 Genetic Basis

5.9 Diagnosis

5.1 Differential Diagnosis

5.11 Diagnostic Guidelines

5.12 Treatment and Management

5.13 Treatment Guidelines

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Incident Population of Waldenstrom Macroglobulinemia

6.3 Epidemiology of Waldenstrom Macroglobulinemia

6.4 The United States

6.4.1 Incident Cases of Waldenstrom Macroglobulinemia (WM) in the United States

6.4.3 Gender-specific cases of Waldenstrom Macroglobulinemia (WM) in the United States

6.4.4 Age-specific Cases of Waldenstrom Macroglobulinemia (WM) in the United States

6.4.6 Gene Mutations in Waldenstrom Macroglobulinemia (WM) in the United States

6.5 EU5

6.5.1 Germany

6.5.4 France

6.5.7 Italy

6.5.10 Spain

6.5.13 The United Kingdom

6.6 Japan

6.6.1 Incident Cases of Waldenstrom Macroglobulinemia (WM) in Japan

6.6.3 Gender-specific cases of Waldenstrom Macroglobulinemia (WM) in Japan

6.6.4 Age-specific Cases of Waldenstrom Macroglobulinemia (WM) in Japan

6.6.6 Gene Mutations in Waldenstrom Macroglobulinemia (WM) in Japan

7 KOL Views

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/k02nwj

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005519/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting